Oral cancer prevention advances with a translational trial of green tea

Cancer Prevention Research

Volumn 2, Issue 11, 2009, Pages 919-921

  Shin, Dong M ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ALPHA TOCOPHEROL; BETA CAROTENE; BIOLOGICAL MARKER; CYCLIN D1; GREEN TEA EXTRACT; KI 67 ANTIGEN; POLYPHENOL; PROTEIN P16; PROTEIN P53; RETINOID; VASCULOTROPIN; PLANT EXTRACT;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; CANCER CELL; CANCER PREVENTION; CANCER RESEARCH; CELL CYCLE ARREST; CHEMOPROPHYLAXIS; CLINICAL RESEARCH; CLINICAL TRIAL; COLON CANCER; DRUG MECHANISM; DRUG MEGADOSE; HEAD AND NECK CANCER; HUMAN; LOW DRUG DOSE; MOUTH CANCER; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TEA; MOUTH TUMOR; NOTE; PHYTOTHERAPY; PRECANCER; TREATMENT OUTCOME;

HUMANS; MOUTH NEOPLASMS; PHYTOTHERAPY; PLANT EXTRACTS; PRECANCEROUS CONDITIONS; TEA; TREATMENT OUTCOME;

EID: 74049097567     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-09-0207     Document Type: Review

References (35)

1. Bode AM, Dong Z. Epigallocatechin 3-gallate and green tea catechins: united they work, divided they fail. Cancer Prev Res 2009;2:514-7.
2. Nakachi K, Suemasu K, Suga K, et al. Influence of drinking green tea on breast cancer malignancy among Japanese patients. Jpn J Cancer Res 1998;89:254-61.
3. Bushman JL. Green tea and cancer in humans: a review of the literature. Nutr Cancer 1998;31:151-9.
4. Chow HH, Cai Y, Hakim IA, et al. Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res 2003;9:3312-9.
5. Sazuka M, Isenmura M, Isemura S. Interaction between the carboxyl-terminal heparin-binding domain of fibronectin and (-)-epigallocatechin gallate. Biosci Biotechnol Biochem 1998;62:1031-2.
6. Hayakawa S, Saeki K, Sazuka M, et al. Apoptosis induction by epigallocatechin gallate involves its binding to Fas. Biochem Biophys Res Commun 2001;285:1102-6.
7. Suxuki Y, Isemura M. Inhibitory effect of epigallocatechin gallate on adhesion of murine melanoma cells to laminin. Cancer Lett 2001;173:15-20.
8. Ermakova S, Chol BY, Chol HS, Kang BS, Bode AM, Dong Z. The intermediate filament protein vimentin is a newtarget for epigallocatechin gallate. J Biol Chem 2005;280:16882-90.
9. Shim JH, Chol HS, Pugliese A, et al. (-)-Epigallocatechin gallate regulates CD3-mediated T cell receptor signaling in leukemia through the inhibition of ZAP-70 kinase. J Biol Chem 2008;283:28370-9.
10. Li M, He Z, Ermakova S, et al. Direct inhibition of insulin-like growth factor-I receptor kinase activity by (-)-epigallocatechin-3-gallate regulates cell transformation. Cancer Epidemiol Biomarkers Prev 2007;16:598-605.
11. Ermakova SP, Kang BS, Choi BY, et al. (-)-Epigallocatechin gallate overcomes resistance to etoposide-induced cell death by targeting the molecular chaperone glucose-regulated protein 78. Cancer Res 2006;66:9260-9.
12. Hastak K, Agarwal MK, Mukhtar H, et al. Ablation of either p21 or Bax prevent p53-dependent apoptosis induced by green tea polyphenol epigallocatechin-3-gallate. FASEB J 2005;19:789-91.
13. Amin AR, Thankur VS, Paul RK, et al. SHP-2 tyrosine phosphatase inhibits p73-dependent apoptosis and expression of a subset of p53 target genes induced by EGCG. Pro Natl Acad Sci U S A 2007;104:5419-24.
14. Hastak K, Gupta S, Ahmad N, et al. Role of p53 and NF-κB in epigallocatechin-3-gallate-induced apoptosis of LNCaP cells. Oncogene 2003;22:4851-9.
15. Roy AM, Baliga MS, Katiyar SK. Epigallocatechin-3-gallate induces apoptosis in estrogen receptor-negative human breast carcinoma cells via modulation in protein expression of p53 and Bax and caspase-3 activation. Mol Cancer Ther 2005;4:81-90.
16. Grandis JR, Argiris A. Targeting angiogenesis from premalignancy to metastases. Cancer Prev Res 2009;2:291-4.
17. Sartippour MR, Heber D, Ma J, et al. Green tea and its catechins inhibit breast cancer xenografts. Nutr Cancer 2001;40:149-56.
18. Leong H, Mathur PS, Greene GL. Green tea catechins inhibit angiogenesis through suppression of STAT3 activation. Breast Cancer Res Treat 2009;117:505-15.
19. Shankar S, Ganapathy S, Hingorani SR, et al. EGCG inhibits growth, invasion, angiogenesis and metastasis of pancreatic cancer. Front Biosci 2008;13:440-52.
20. Masuda M, Suzui M, Weinstein IB. Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clin Cancer Res 2001;7:4220-9.
21. Adachi S, Nagao T, Ingolfsson HI, et al. The inhibitory effect of (-)-epigallocatechin gallate on activation of the epidermal growth factor receptor is associated with altered lipid order in HT29 colon cancer cells. Cancer Res 2007;67:6493-501.
22. Tsao AS, Liu D, Martin J, et al. Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. Cancer Prev Res 2009;2:931-41.
23. Sporn MB, Dunlop NM, Newton DL. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976;35:1332-8.
24. Hong WK, Endicott J, Itri LM, et al. 13-cis retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986;315:1501-5.
25. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with β carotene to prevent oral carcinogenesis. N Engl J Med 1993;328:15-20.
26. Hong WK, Lippman SM, Itri LM, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;322:795-801.
27. Papadimitrakopoulou VA, Lee JJ, William WN, Jr., et al. Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without β-carotene in oral premalignancy. J Clin Oncol 2009;27:599-604.
28. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001;93:605-8.
29. Khuri FR, Lee JJ, Lippman SM, et al. Randomized phase III trial of lowdose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients. J Natl Cancer Inst 2006;98:441-50.
30. Shin DM, Khuri FR, Murphy B, et al. Combined interferon-α, 13-cis-retinoic acid and alfatocoferal in locally advanced head and neck squamous cell carcinoma: novel bioadjuvant phase II trial. J Clin Oncol 2001;19:3010-7.
31. Masuda M, Suzui M, Lim JT, et al. Epigallocatechin-3-gallate decreases VEGF production in head and neck and breast carcinoma cells by inhibiting EGFR-related pathways of signal transduction. J Exp Ther Oncol 2002;2:350-9.
32. Izzo JG, Papadimitrakopoulou VA, Liu DD, et al. Cyclin D1 genotype, response to biochemoprevention, and progression rate to upper aerodigestive tract cancer. J Natl Cancer Inst 2003;95:198-205.
33. Mao L, El-Naggar AK, Papadimitrakopoulou V, et al. Phenotype and genotype of advanced premalignant head and neck lesions after chemopreventive therapy. J Natl Cancer Inst 1998;90:1545-51.
34. Sporn MB, Hong WK. Clinical prevention of recurrence of colorectal adenomas by the combination of difluoromethylornithine and sulindac: an important milestone. Cancer Prev Res 2008;1:9-11.
35. Amin RA, Khuri FR, Chen ZG, Shin DM. Synergistic growth inhibition of squamous cell carcinoma of the head and neck by erlotinib and EGCG: the role of P53 dependent inhibition of nuclear factor-κB. Cancer Prev Res 2009;6:538-45.